TO: Maine Immunization Providers



TO: Maine Immunization Providers

FROM: Maine Immunization Program

SUBJECT: ACIP Immunization Changes and Updates

DATE: September 16th, 2009

On June 24th, 2009 the Advisory Committee on Immunization Practices (ACIP) made several changes to the current immunization schedule in the United States. The changes are summarized below:

New IPV Recommendations

• No change in the recommended IPV schedule of four doses at age 2 months, 4 months, 6 months through 18 months, and 4 through 6 years.

• Minimum interval between 3rd and 4th doses is now 6 calendar months, not 4 weeks.

• Minimum age for final IPV dose is now 4 years old.

• When 4 doses of IPV are administered before the 4th birthday an additional dose of age appropriate IPV should be given on or after the 4th birthday.

• Minimum interval from dose 4 to dose 5 should be at least 6 calendar months.

Pentacel Vaccine Recommendations

• Licensed by the FDA for doses 1 through 4 of the DTaP series among children 6 weeks through 4 years of age.

• Should not be used for the 5th dose of the DTaP series or for children 5 years or older.

KINRIX Vaccine Recommendations

• Only approved for the 5th dose of the DTaP series and the 4th dose of the IPV series.

• Any use of KINRIX for any dose except the 5th dose of DTaP and the 4th dose of IPV should be considered a vaccine administration error.

• If KINRIX is inadvertently administered as an earlier dose in the series the dose may be counted as valid and does not need to be repeated if the minimum age and minimum interval since the prior dose are met.

New Pneumococcal Polysaccharide Vaccine (PPSV) Recommendations

• All adults 19 years and older with asthma regardless of severity.

• Available data do not support asthma as an indicate for PPSV among persons younger than 19 years.

• All adults 19 years and older who smoke cigarettes.

• Rountine revaccination of immmunocompetent persons is not recommended.

• Revaccination recommended for persons 2 years of age or older who are at highest risk for serious pneumococcal infection.

• Revaccation is a 1 time event.

• 5 years or longer after first dose (interval applies to persons of all ages)

New Meningococcal Vaccine Recommendations

• Children through 18 years of age who received their first dose of MCV or MPSV at age 2 through 6 years and remain at increased risk for meningococcal disease should receive an additional dose of MCV 3 years after their first.

• Persons through age 55 years who receive a dose of MCV or MPSV after age 6 years and remain at increased risk for meningococcal disease should receive an additional dose of MCV 5 years after their previous dose.

• MCV revaccination does not apply to children who previously received MCV and who will be a freshman living in a dormitory.

For the PowerPoint presentation on new 2009 immunization recommendations go to:

For the resource page on new 2009 immunization recommendations go to:



If you have any questions or concerns please call the Maine Immunization Program at 287-3746 or 1-800-867-4775

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download